SI
YARW

Sofinnova Investments’s Yarrow Bioscience YARW Stock Holding History

Sofinnova Investments’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-202
Closed -$1.26M – 87
2020
Q2 		$1.26M Buy
202
+34
+20% +$230K 0.08% 68
2020
Q1 		$1.62M Buy
+168
New +$2.63M 0.15% 57

Other funds holding YARW

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Sofinnova Investments's YARW Position: Q3 2020 in Review

Sofinnova Investments sold out of Yarrow Bioscience (YARW) in Q3 2020, closing a stake of 202 shares — an estimated $1.26M sold.

Sofinnova Investments first reported a position in YARW in Q1 2020 and held it in 2 quarters. The position peaked at $1.62M in Q1 2020. 97 funds tracked by Wall St. Rank hold YARW as of Q3 2020.

  • Sofinnova Investments reported no remaining Yarrow Bioscience position as of Q3 2020 after selling out during the quarter.
  • Sofinnova Investments sold 202 Yarrow Bioscience shares in Q3 2020, an estimated $1.26M.
  • Sofinnova Investments first reported a position in Yarrow Bioscience in Q1 2020 and held it in 2 quarters.
  • Sofinnova Investments's Yarrow Bioscience position peaked at $1.62M in Q1 2020.
  • 97 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q3 2020.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.